Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus VESICARE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus VESICARE.
CANTIL vs VESICARE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Competitive antagonist at muscarinic acetylcholine receptors (M1-M5), with selectivity for M3 receptors over M2. Inhibits bladder detrusor muscle contraction, increasing bladder capacity and reducing urinary urgency.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
5 mg orally once daily; may increase to 10 mg once daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life is approximately 45 hours (range 33–57 hours), supporting once-daily dosing.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Approximately 70% of an oral dose is excreted in urine (mainly as metabolites, <15% unchanged) and 25% in feces.
Category C
Category C
Anticholinergic / Antispasmodic
Anticholinergic